InMed Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
INM Nasdaq 2836 www.inmedpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance - Sep 18th, 2026 2:45 pm
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update - Sep 9th, 2026 2:30 pm
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline - Jul 22nd, 2026 5:00 am
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 - Jul 6th, 2026 4:20 pm
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements - Jun 4th, 2026 3:00 pm
INM Stock Alert: What to Know as InMed, Mentari Announce Merger - May 20th, 2026 11:01 am
/C O R R E C T I O N -- InMed Pharmaceuticals/ - May 20th, 2026 8:34 am
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM) - May 19th, 2026 8:37 am
A migraine drugmaker heads to the public markets through reverse merger - May 19th, 2026 5:19 am
InMed Pharmaceuticals Amends Preferred Investment Options - May 19th, 2026 4:00 am
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update - May 6th, 2026 4:00 pm
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Mar 27th, 2026 3:05 pm
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program - Mar 23rd, 2026 5:30 am
Sidoti Events, LLC's March Small-Cap Virtual Conference - Mar 18th, 2026 6:00 am
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial - Mar 9th, 2026 5:30 am
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline - Mar 6th, 2026 3:04 pm